首页> 外文期刊>ACS applied materials & interfaces >Choline Derivate-Modified Doxorubicin Loaded Micelle for Glioma Therapy
【24h】

Choline Derivate-Modified Doxorubicin Loaded Micelle for Glioma Therapy

机译:胆碱衍生物修饰的阿霉素负载胶束用于胶质瘤治疗

获取原文
获取原文并翻译 | 示例
           

摘要

Ligand-mediated polymeric micelles have enormous potential for improving the efficacy of glioma therapy. Linear dendritic drug polymer conjugates composed of doxorubicin (DOX) and polyethylene glycol (PEG) were synthesized with or without modification of choline derivate (CD). The resulting MeO-PEG-DOX8 and CD-PEG-DOX8 could self-assemble into polymeric micelles with a nanosized diameter around 30 nm and a high drug loading content up to 40.6 and 32.3%, respectively. The optimized formulation 20% CD-PEG-DOX8 micelles had superior cellular uptake and antitumor activity against MeO-PEG-DOX8 micelles. The subcellular distribution using confocal study revealed that 20% CD-PEG-DOX8 micelles preferentially accumulated in the mitochondria. Pharmacokinetic study showed area under the plasma concentration time curve (AUC(0-t),) and C-max for 20% CD-PEG-DOX8 micelles and DOX solution were 1336.58 +/- 179.43 mg/L.h, 96.35 +/- 3.32 mg/L and 1.40 +/- 0.19 mg/L.h, 1.15 +/- 0.25 mg/L, respectively. Biodistribution study showed the DOX concentration of 20% CD-PEG-DOX8 micelles treated group at 48 h was 2.37-fold higher than that of MeO-PEG-DOX8 micelles treated group at 48 h and was 24 fold-higher than that of DOX solution treated group at 24 h. CD-PEG-DOX8 micelles (20%) were well tolerated with reduced cardiotoxicity, as evaluated in the body weight change and HE staining studies, while they induced most significant antitumor activity with longest media survival time in an orthotopic mouse model of U87-luci glioblastoma model as displayed in the bioluminescence imaging and survival curve studies. Our findings consequently indicated that 20% CD-PEG-DOX8 micelles are promising drug delivery system for glioma chemotherapy.
机译:配体介导的聚合物胶束具有改善神经胶质瘤治疗功效的巨大潜力。合成了由阿霉素(DOX)和聚乙二醇(PEG)组成的线性树突状药物聚合物共轭物,修饰或不修饰胆碱衍生物(CD)。所得的MeO-PEG-DOX8和CD-PEG-DOX8可以自组装成聚合物胶束,其纳米直径约为30 nm,高载药量分别达到40.6%和32.3%。优化的20%CD-PEG-DOX8胶束配方具有优异的细胞摄取和抗MeO-PEG-DOX8胶束活性。使用共聚焦研究的亚细胞分布表明,20%CD-PEG-DOX8胶束优先聚集在线粒体中。药代动力学研究显示,血浆浓度时间曲线下的面积(AUC(0-t),)和20%CD-PEG-DOX8胶束和DOX溶液的C-max为1336.58 +/- 179.43 mg / Lh,96.35 +/- 3.32 mg / L和1.40 +/- 0.19 mg / Lh,1.15 +/- 0.25 mg / L。生物分布研究表明,在48 h,20%CD-PEG-DOX8胶束处理组的DOX浓度比MeO-PEG-DOX8胶束处理组的48小时高2.37倍,比DOX溶液高24倍。治疗组在24小时。在体重变化和HE染色研究中评估,CD-PEG-DOX8胶束(20%)具有良好的耐受性,并具有降低的心脏毒性,而在U87-luci的原位小鼠模型中,它们诱导了最显着的抗肿瘤活性,具有最长的培养基存活时间在生物发光成像和生存曲线研究中显示的胶质母细胞瘤模型。因此,我们的发现表明20%CD-PEG-DOX8胶束是用于神经胶质瘤化疗的有希望的药物递送系统。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号